INTRODUCTION {#S1}
============

Cancer-associated fibroblasts are a heterogeneous population of tumor stromal cells that undergo myofibroblastic cytodifferentiation acquiring phenotypic characteristics of activated fibroblasts ([@R1]-[@R4]). In addition to the fibroblast activation protein seprase ([@R5]) and α-smooth muscle actin (α-SMA), some cancer-associated fibroblasts express desmin and smooth muscle myosin heavy chain isoforms ([@R1]). However, they lack expression of high molecular weight-caldesmon which distinguishes them from pericytes ([@R6]). Cancer-associated fibroblast infiltration has been associated with metastasis and poor clinical outcome in colon ([@R7];[@R8]), breast ([@R9];[@R10]), prostate ([@R11]) and other adult cancers ([@R12]-[@R14]). The capacity of cancer-associated fibroblasts to promote tumor growth, angiogenesis, and invasion is mediated by multiple factors, including hepatocyte growth factor (HGF) ([@R15]-[@R17]) and stromal-cell derived factor-1 (SDF-1) ([@R9]). However, the role of cancer-associated fibroblasts has not previously been evaluated in neuroblastoma, a pediatric cancer in which clinical behavior is strongly impacted by the cellular composition of tumor stroma.

The current World Health Organization classification of neuroblastoma is based on histologic criteria, defined by the International Neuroblastoma Pathology Committee ([@R18]-[@R20]). Four diagnostic categories of Schwannian stroma rich/dominant tumors include mature and maturing ganglioneuroma, and ganglioneuroblastoma of intermixed and nodular type. Three categories of Schwannian Stroma-poor neuroblastoma tumors include differentiating, poorly differentiated and undifferentiated ([@R18];[@R21]). Tumor aggressiveness is linked to the International Neuroblastoma Pathology Committee histologic features ([@R18]). With the exception of nodular ganglioneuroblastoma, all Schwannian Stroma-rich neuroblastoma tumors are associated with favorable prognosis ([@R22];[@R23]). We have previously demonstrated correlation between low vascular density and the absence of microvascular proliferation in Schwannian Stroma-rich tumors ([@R24]). In contrast, high vascular index and abnormal blood vessel structure with microvascular proliferation are associated with clinically aggressive Schwannian Stroma-poor neuroblastoma tumors ([@R24];[@R25]). The mechanisms governing the regulation of angiogenesis and tumor phenotype in neuroblastoma are not fully understood, but we and others have shown that Schwann cells secrete angiogenic inhibitors ([@R26]-[@R28]) In addition, we have demonstrated that angiogenesis is inhibited in a novel neuroblastoma xenograft model in which mouse Schwann cells were induced to infiltrate the tumor by engrafting neuroblastoma cells in the sciatic nerve of nude mice ([@R29]).

To investigate the role cancer-associated fibroblasts lay in neuroblastoma angiogenesis and their relationship to stromal Schwann cells, we quantified cancer-associated fibroblasts in 14 Schwannian Stroma-rich and 46 Schwannian Stroma-poor neuroblastoma tumors. We also quantified the number of cancer-associated fibroblasts in a novel neuroblastoma xenograft model in which murine Schwann cells were induced to infiltrate into the tumor stroma. Similar to previous studies, microvascular proliferation was not detected in Schwannian Stroma-rich/dominant neuroblastoma tumors. We also found that high numbers of cancer-associated fibroblasts were inversely associated with the presence of Schwann cells in both the primary human neuroblastoma tumors and in the xenograft model. Our results suggest that cancer-associated fibroblasts play a role in regulating neuroblastoma angiogenesis and that Schwann cells may prevent the accumulation and activation of fibroblasts in neuroblastoma tumors.

MATERIALS AND METHODS {#S2}
=====================

Patients and Tumor Specimens {#S3}
----------------------------

Patients were selected based on the availability of adequate full tissue sections from the primary tumor. Sections from 60 primary neuroblastoma, ganglioneuroblastoma, and ganglioneuroma tumors were obtained from Children's Memorial Hospital in Chicago at the time of diagnosis, before administration of chemotherapy. Patients were diagnosed between 1986 and 2005. Medical records were reviewed to obtain information regarding patient age, sex, tumor stage, histology, *MYCN* gene status, and outcome. The CMH Institutional Review Board approved this study.

Tumors were grouped into six diagnostic categories recognized by INPC ([@R19]) and staged according to the International Neuroblastoma Staging System ([@R30]). *MYCN* gene status was determined in the Children's Oncology Group (COG) neuroblastoma Reference Laboratory using FISH ([@R31]). Tumors were classified as either favorable or unfavorable histology according to the criteria described by INPC ([@R19]).

Cell Culture {#S4}
------------

The biological and genetic characteristics of the *MYCN* amplified human neuroblastoma cell line, SMS-KCNR, used in this study have been previously described ([@R32]). Cells were grown at 5% CO~2~ in RPMI 1640 (Invitrogen, Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine serum, L-Glutamine, and antibiotics.

Sciatic Nerve Engraftment of Neuroblastoma Xenografts {#S5}
-----------------------------------------------------

Sciatic nerve engraftment was done as previously described ([@R29]). Briefly, following anesthesia the left sciatic nerve was surgically exposed and 5 × 10^5^ SMS-KCNR neuroblastoma cells were microinjected either outside or inside the sciatic nerve. Tumors were measured once a week and tumor volume was determined as length × width^2^/2. Animals were sacrificed when tumors were \>500 mm^3^, and the xenografts were harvested and characterized in Liu *et al*. ([@R29]). All animals were treated according to NIH guidelines for animal care and use, and protocols were approved by the Animal Care and Use Committee at Northwestern University.

Histologic Evaluation {#S6}
---------------------

Adjacent 4 μm sections from formalin-fixed paraffin-embedded tumor tissues were deparaffinized, rehydrated and stained with either hematoxylin and eosin (H&E) or Masson's Trichrome([@R34]), which highlighted variable degrees of fibrocollagenenous stroma. The entire area of each section was examined histologically for Schwannian and fibrovascular stroma, vascular morphology and neuroblast differentiation by a pathologist (RZ). Sixty human tumors were examined, including 42 neuroblastomas (23 differentiating, 14 poorly differentiated and 5 undifferentiated), 11 ganglioneuroblastomas (7 intermixed and 4 nodular), and 7 ganglioneuromas. Ten of the neuroblastoma xenografts were engrafted inside the sciatic nerve and 9 were engrafted outside the sciatic nerve and served as controls.

Tumors were classified as having microvascular proliferation when blood vessels were present with thickened walls containing a complete layer of hypertrophic endothelial cells plus additional layers of vascular mural cells as previously described ([@R24]). The degree of microvascular proliferation varied from slight to florid ([@R24];[@R33]). Tumors without microvascular proliferation contained only thin-walled vessels with no more than one layer of flat, spindle shaped endothelial cells. Small vessels forming complex glomeruloid structures were present in tumors with high microvascular proliferation. Special care was taken to avoid confusing tangentially cut vessels. The type of tumor stroma (Schwannian vs. fibrovascular) surrounding the vessels was carefully analyzed. Arteries, veins and microvascular proliferation noted within lymph nodes or in intense inflammatory infiltrates were excluded from analysis.

Immunohistochemistry {#S7}
--------------------

Accumulation of cancer-associated fibroblasts in tumors was further evaluated by examining adjacent sections from all human tumors and xenografts stained by immunohistochemistry with α-SMA and high-molecular weight caldesmon. For α-SMA staining, 4μm sections were deparaffinized and heat-induced antigen retrieval was carried out in a steamer for 20 minutes in Target Retrieval Solution pH 9 (DakoCytomation, Carpinteria, CA). For caldesmon staining, deparaffinized sections were treated for 5 minutes with Proteinase K (DakoCytomation) at a concentration of 0.04 mg/ml, followed by heat-induced antigen retrieval in a steamer for 20 minutes in Target Retrieval Solution pH 6 (DakoCytomation). Slides were immersed in peroxidase block solution (DakoCytomation) and, incubated for 1 hour at room temperature with monoclonal mouse antibodies for α-SMA (clone 1A4, DakoCytomation) or caldesmon (clone h-CD, DakoCytomation) at 1:50 dilution. Slides were developed with the EnVision+/HRP anti-mouse detection system (DakoCytomation) and counterstained with Gill's hematoxylin.

Quantification of α-SMA Positive Cells in Human Neuroblastoma Tumors {#S8}
--------------------------------------------------------------------

Tissue sections immunostained for α-SMA were scanned at 200X magnification on the Automated Cellular Imaging System (ACIS II, ChromaVision, Clarient, San Juan Capistrano, CA). To quantify α-SMA positive cells, a protocol for detection was defined by setting color-specific thresholds for both dark and light brown staining using control slides. For each sample, ratios of the areas positively stained for α-SMA to the entire area were calculated from the areas provided by ACIS II software and then converted to percentages. The mean percentage of α-SMA positive areas +/− the standard deviation was calculated for histological subsets of neuroblastoma tumors and the Student's *t*-test was used to compare the means. Furthermore, cancer-associated fibroblast number was classified as either low (≤1.0%) or high (\>1.0) based on the percentage of α-SMA positive areas for individual tumors. Chi-square tests were used to compare tumor categories.

Quantification of α-SMA Positive Cells in Neuroblastoma Xenografts {#S9}
------------------------------------------------------------------

Cells expressing α-SMA were quantified in neuroblastoma xenografts engrafted inside the sciatic nerve and having stromal Schwann cell infiltration and in controls by counting 10 low-power (×200 magnification) fields. The total number of α-SMA positive cells/mm^2^ was calculated. The mean number of α-SMA positive cells/mm^2^ in the xenografts with stromal Schwann cell infiltration and controls was compared and statistical significance was analyzed using the Student's *t*-test.

Statistical Analysis {#S10}
--------------------

Associations between cancer-associated fibroblast number and various established clinico-pathologic prognostic factors of neuroblastoma were analyzed using the Chi-square or Student's t-tests. Ganglioneuromas were included only in analyses related to stroma histology and microvascular proliferation. Patients were stratified into 2 risk groups based on stage, age, and *MYCN* status. The non-high-risk group included patients with non-amplified *MYCN* stage 1, 2 and 3 tumors, and infants with stage 4 and 4s neuroblastoma that lacked *MYCN* amplification. Patients with stage 3 *MYCN*-amplified tumors and children older than 1 year of age with stage 4 disease were classified as high-risk.

RESULTS {#S11}
=======

Cancer-Associated Fibroblast Levels Are Associated with Schwannian Stroma-Poor Histology {#S12}
----------------------------------------------------------------------------------------

The vast majority of α-SMA positive cells in the Schwannian Stroma-rich/dominant tumors were pericytes as evidenced by their association with endothelial cells and positive h-caldesmon expression. In the ganglioneuroma tumors, scant fibrovascular bands with single layers of pericytes lining thin-walled vessels were seen ([Fig. 1](#F1){ref-type="fig"}). Cancer-associated fibroblasts, which express α-SMA but not h-caldesmon, were only rarely detected in these tumors. The mean percent α-SMA positive area was low in these Schwannian Stroma-dominant tumors, using the defined cut-off value of ≤1.0% (0.79% ± 0.19; [Fig.1](#F1){ref-type="fig"}). Similarly, rare scattered cancer-associated fibroblasts were present in the vicinity of maturing neuroblasts and within delicate fibrovascular bands in the ganglioneuroblastoma intermixed tumors. The mean percent α-SMA positive area for the 7 ganglioneuroblastoma intermixed tumors was also low (0.96% ± 0.31).

In contrast, staining with α-SMA and h-caldesmon demonstrated high numbers of cancer-associated fibroblasts (α-SMA+/hCD--) in the Schwannian Stroma-poor nodules within ganglioneuroblastoma nodular tumors ([Table 1](#T1){ref-type="table"}). These cells constituted a majority of the stromal cell populations within thick fibrovascular bands and the mean percent α-SMA positive area was high (2.08% ± 0.34). More dramatic increases in cancer-associated fibroblasts were manifested in the Schwannian Stroma-poor neuroblastoma tumors and the mean percent α-SMA positive area was high in this subset of tumors (2.39% ± 1.78 in differentiated tumors; 2.41% ± 1.64 in poorly differentiated tumors; 3.40% ± 2.19 in undifferentiated tumors). Approximately 85-90% of the stromal cells in the Schwannian Stroma-poor neuroblastoma tumors were α-SMA positive, either scattered amongst the neuroblasts or distributed within thick bands of fibrovascular stroma. Masson Trichrome special stain highlighted fibrocollagenous elements within the fibrovascular stroma of Schwannian Stroma-poor neuroblastoma tumors ([Fig. 1](#F1){ref-type="fig"}). There is a significant difference of Cancer Associated Fibroblast levels between Schwannian Stroma-rich and Schwannian Stroma-poor groups (p\< 0.001), as shown in [Fig.1](#F1){ref-type="fig"} and [Table 1](#T1){ref-type="table"}.

Cancer Associated Fibroblast Levels are Associated with Microvascular Proliferation in Human Neuroblastoma Tumors {#S13}
-----------------------------------------------------------------------------------------------------------------

Microvascular proliferation was present in 33 of the 42 Schwannian Stroma-poor neuroblastoma tumors and in the stroma-poor nodules of the 4 ganglioneuroblastoma nodular tumors evaluated. In contrast, microvascular proliferation was not detected in the ganglioneuroma and ganglioneuroblastoma intermixed tumors. Of the 22 tumors without microvascular proliferation, 13 (68%) had low cancer-associated fibroblast levels, whereas high numbers of cancer-associated fibroblasts were seen in 33 (84%) of the 38 tumors with microvascular proliferation (p\<0.001). Interestingly, cancer-associated fibroblasts were observed in the vicinity of blood vessels with microvascular proliferation ([Fig.2](#F2){ref-type="fig"}).

Heterogeneity of Cancer-Associated Fibroblast Levels in Human Neuroblastoma Tumors {#S14}
----------------------------------------------------------------------------------

[Table 1](#T1){ref-type="table"} categorizes the extent of cancer-associated fibroblast accumulation according to the available clinical and biological characteristics of the human neuroblastoma tumors in the CMH series. Seventeen patients had high-risk disease and 27 patients had non high-risk disease. The estimated 5-year overall survival for this small cohort of high-risk patients was 61% and 100% for the subset of non-high risk children, which is higher than expected. A trend was seen associating presence of cancer-associated fibroblasts with unfavorable histology (p=0.18) but statistical significance was not reached, most likely due to the small number of samples evaluated. In this series of patients, no statistically significant associations were found between high cancer-associated fibroblast levels and *MYCN* amplification (p=0.75), age (p=0.51), stage (p=0.49), risk group (p=0.88) or survival (p=0.89).

Cancer-Associated Fibroblast Accumulation is Decreased in Neuroblastoma Xenografts with Schwannian Stroma {#S15}
---------------------------------------------------------------------------------------------------------

We have previously shown that murine Schwann cells infiltrate the stroma of neuroblastoma xenografts engrafted into the sciatic nerve and that these tumors have inhibited angiogenesis compared to control tumors engrafted outside the sciatic nerve ([@R29]). Immunohistochemistry with anti-α-SMA antibody demonstrated widespread cancer-associated fibroblast infiltration in control neuroblastoma xenografts engrafted outside the sciatic nerve ([Fig.3A and 3B](#F3){ref-type="fig"}). Interestingly, significantly fewer cancer-associated fibroblasts were detected in the xenografts in which Schwann cells were induced to infiltrate the tumor by engraftment in the sciatic nerve ([Fig.3C and 3D](#F3){ref-type="fig"}). The number of α-SMA positive cells/mm^2^ was \~7-fold less in xenografts engrafted inside the sciatic nerve (n=10) compared to controls (51 ± 30 vs 368 ± 105,respectively; p\<0.001) ([Fig.3E](#F3){ref-type="fig"}).

DISCUSSION {#S16}
==========

In neuroblastoma, the amount of Schwannian stroma strongly impacts prognosis ([@R18]), which has been emphasized in the classification system of Shimada ([@R34]) and the International Neuroblastoma Pathology Classification ([@R35]). The biologic mechanisms that underlie the more benign clinical behavior in tumors with abundant Schwannian stroma are not fully understood. However, we and others have shown that Schwann cells secrete factors that are capable of inducing neuroblastoma differentiation and inhibiting angiogenesis ([@R26];[@R28]). In contrast to clinically aggressive Schwannian Stroma -poor tumors which are highly angiogenic, the vascular index of Schwannian Stroma-rich/dominant tumors is low. We have also shown that structurally abnormal blood vessels with microvascular proliferation, which are commonly detected in Schwannian Stroma-poor tumors, are rare in Schwannian Stroma-rich/dominant neuroblastomas ([@R24]). We now demonstrate that significantly higher numbers of cancer-associated fibroblasts are present in Schwannian Stroma-poor tumors compared to Schwannian Stroma -rich/dominant neuroblastomas, consistent with the established pro-angiogenic function of cancer-associated fibroblasts. Although we have previously shown high vascularity to be associated with clinically aggressive disease and poor outcome in neuroblastoma ([@R24];[@R25]) in the small series of patients analyzed in this study associations between levels of cancer-associated fibroblasts and other established prognostic factors or outcome have not reached statistical significance.

In order to further explore the seemingly antagonistic relationship between Schwannian stroma and accumulation of cancer-associated fibroblasts, we examined neuroblastoma xenografts in which Schwann cells had been induced to infiltrate into the tumor stroma by surgical engraftment of the neuroblastoma cells within the sciatic nerves of nude mice ([@R29]). We had previously documented anti-proliferative and anti-angiogenic effects in these sciatic nerve-engrafted tumors ([@R29]). A dramatic 7-fold decrease in the number of cancer-associated fibroblasts was seen in the neuroblastoma xenografts with stromal Schwann cell infiltration compared to controls. The mechanisms underlying the inverse relationship between high cancer-associated fibroblasts levels and Schwann cells in tumor stroma remain to be elucidated. The altered tumor microenvironment within the sciatic nerve may either have reduced the migration of myofibroblastic precursors into the NB xenografts, or inhibited their activation, via one or more Schwann cell-derived factors with tumor suppressive activity ([@R26];[@R28];[@R29]).

Cancer-associated fibroblasts have been identified in breast, colon, lung, and prostate cancers, and there is significant evidence demonstrating that these cells actively promote tumor growth and angiogenesis ([@R36];[@R37]). The origin of tumor myofibroblasts and the underlying mechanisms that lead to their activation are still not well understood. There are reports suggesting that the existing fibroblasts in the tissue stroma can undergo activation ([@R38]). There is also evidence to suggest that myofibroblasts may originate from the vascular smooth muscles and pericytes ([@R39]). Studies have shown that transforming growth factor β (TGFβ) and platelet derived growth factor (PDGF), which are key molecules in the wound healing process, take part in the activation of fibroblasts ([@R13]). Previous studies from our laboratory have demonstrated that Secreted Protein Acidic and Rich in Cysteine (SPARC), an extracellular matrix protein that is secreted by Schwann cells, is capable of preventing fibroblast activation *in vitro* and *in vivo* ([@R27]).

Taken together, our results indicate that, similar to other types of carcinoma, cancer-associated fibroblasts promote tumor angiogenesis in neuroblastoma. Furthermore, the paucity of cancer-associated fibroblasts in Schwannian Stroma-rich/dominant neuroblastomas that characteristically have low vascularity suggests that Schwann cells may block accumulation and activation of cancer-associated fibroblasts. A deeper understanding of the mechanisms regulating formation of cancer-activated stroma may guide future development of anti-stromal therapeutic strategies in children with aggressive neuroblastoma tumors.

![Cancer Associated Fibroblasts in Schwannian Stroma-poor neuroblastoma tumors\
Representative sections of human ganglioneuroma\[GNR\] (A-D), ganglioneuroblastoma intermixed\[GNBI\] (E-H), ganglioneuroblastoma nodular\[GNBN\] (I-L), and neuroblastoma tumors that are differentiating\[NBD\] (M-P), poorly differentiated\[NBPD\] (Q-T), and undifferentiated\[NBU\] (U-W) tumors stained with H&E (A, E, I, M, Q, and U), Masson Trichrome special stain (B, F, J, N, R, and V), α-SMA which reveals cancer-associated fibroblasts and pericytes (C, G, K, O, S, and W), and high molecular weight caldesmon, which stains pericytes, but not cancer-associated fibroblasts (D, H, L, P, and T). The mean (±standard deviation) percent of α-SMA positive areas per total tumor area analyzed for each tumor type are shown in the bar graph (X). α-SMA positive, caldesmon-negative cancer-associated fibroblasts are rare in the Schwannian Stroma\[SS\]-dominant ganglioneuroma (C, D and X) and Schwannian Stroma -rich ganglioneuroblastoma intermixed (G/H and X) tumors. Significantly more cancer-associated fibroblasts are present in Schwannian Stroma -poor tumors (K, L, S, T, W). Bands of fibrocollagenous stroma are thin and delicate in ganglioneuroma and ganglioneuroblastoma intermixed tumors, but are thick and support microvascular proliferation in ganglioneuroblastoma nodular and neuroblastoma tumors (pale blue B and F vs. J, N, R and V). Cancer-associated fibroblasts constitute the majority of stromal cells within fibrovascular stroma (O, S and W). Original magnification x200 (A-L, T) and x400 (P).](nihms-97522-f0001){#F1}

![Cancer-associated fibroblasts in human neuroblastomas with microvascular proliferation\
Representative sections of differentiating neuroblastoma\[NBD\] (A), poorly differentiated neuroblastoma\[NBPD\] (B), ganglioneuroma\[GNR\] (C) and ganglioneuroblastoma intermixed\[GNBI\] (D) tumors immunostained for α-SMA. The mean (±standard deviation) percent of α-SMA -positive areas per total tumor areas analyzed for tumors with microvascular proliferation\[MVP\] are shown in the bar graph (E). Significantly more α-SMA -positive cancer-associated fibroblasts are present in the tumors with microvascular proliferation (A, B, and E) as compared to tumors without microvascular proliferation (C, D, and E) (p\<0.001). The cancer-associated fibroblasts are present within bands of fibrovascular stroma supporting microvascular proliferation (A and B). Original magnification x400.](nihms-97522-f0002){#F2}

![Cancer Associated Fibroblasts are decreased in neuroblastoma xenografts with infiltrating murine Schwann cells\
Representative sections of SMS-KCNR tumors engrafted outside (A and B) versus inside (C and D) the sciatic nerve immunostained for α-SMA. The mean (±SD) number of α-SMA -positive cells per mm^2^ of the tumors engrafted outside (n=9) and inside (n=10) the sciatic nerve are shown in the bar graph (E). Significantly more α-SMA -positive Cancer Associated Fibroblasts are present in tumors engrafted outside (A and B) as compared to inside the sciatic nerve (C and D) (p\<0.001 for total α-SMA -positive cells). Original magnification x200 (A, C) and x400 (B, D).](nihms-97522-f0003){#F3}

###### 

Associations between levels of CAFs, Schwannian Stroma, MVP and clinical risk factors in the CMH cohort

  Characteristic                                    CAFs Low   CAFs High   Total   P
  ------------------------------------------------- ---------- ----------- ------- ---------
  **Diagnosis**                                                                    \<0.001
  NB(A+B+C)                                         9 (21%)    33 (78%)    42      
  A. Undifferentiated NB                            1 (20%)    4 (80%)     5       
  B. Poorly differentiated NB                       2 (14%)    12 (86%)    14      
  C. Differentiating NB                             6 (26%)    17 (74%)    23      
  Nodular GNB                                       0 (0%)     4 (100%)    4       
  Intermixed GNB                                    5 (71%)    2 (29%)     7       
  GNR                                               7 (100%)   0 (0%)      7       
                                                                                   
  **Schwannian Stroma**                                                            \<0.001
  NB+nodular GNB, SS-poor                           9 (20%)    37 (80%)    46      
  Intermixed GNB+GNR, SS-rich                       12 (86%)   2 (14%)     14      
                                                                                   
  **Microvascular Proliferation**                                                  \<0.001
  NB+intermixed GNB+GNR, no MVP                     13 (60%)   9 (40%)     22      
  NB and nodular GNB with MVP                       5 (16%)    33 (84%)    38      
                                                                                   
  **Age** [\*](#TFN2){ref-type="table-fn"}                                         0.51
  \< 12 months                                      4 (21%)    15 (79%)    19      
  ≥ 12 months                                       10 (29%)   24 (71%)    34      
                                                                                   
  **Risk Group** [\*](#TFN2){ref-type="table-fn"}                                  0.88
  High-Risk                                         3 (20%)    12 (80%)    15      
  Non High-Risk                                     7 (28%)    18 (72%)    25      
                                                                                   
  ***MYCN*** [\*](#TFN2){ref-type="table-fn"}                                      0.75
  Amplified                                         2 (22%)    7 (78%)     9       
  Non-amplified                                     11 (28%)   29 (72%)    40      
                                                                                   
  **Histology** [\*](#TFN2){ref-type="table-fn"}                                   0.18
  Unfavorable                                       3 (13%)    20 (86%)    23      
  Favorable                                         8 (29%)    20 (71%)    28      
                                                                                   
  **Stage** [\*](#TFN2){ref-type="table-fn"}                                       0.49
  1, 2, 3 , 4S                                      10 (29%)   24 (70%)    34      
  4                                                 3 (20%)    12 (80%)    15      
                                                                                   
  **Survival** [\*](#TFN2){ref-type="table-fn"}                                    0.89
  Dead                                              2 (29%)    5 (71%)     7       
  Alive                                             12 (26%)   34 (74%)    46      

NB: neuroblastoma; GNB: ganglioneuroblastoma; GNR:ganglioneuroma; SS: Schwannian Stroma

only NB+GNB
